Pfizer to Present New Clinical Data on COVID-19, RSV, and Pneumococcal Vaccines at IDWeek 2025
Pfizer Inc. will present new clinical data on its infectious disease portfolio at IDWeek 2025 in Atlanta from October 19-22, 2025. The presentations will include results from 46 abstracts on vaccines and therapeutics for diseases like COVID-19, RSV, and pneumococcal disease. Key findings include the effectiveness of the JN.1-adapted BNT162b2 COVID-19 vaccine in high-risk groups and the real-world effectiveness of the Abrysvo vaccine against RSV-related diseases. Results will be shared in oral and poster sessions at the conference.
Pfizer Inc. has announced that it will present new data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, scheduled to take place in Atlanta from October 19-22, 2025. The presentations will include results from 46 abstracts, covering clinical studies and real-world analyses related to vaccines and therapeutics for diseases such as COVID-19, respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, and meningococcal disease. Notable presentations include findings on the effectiveness of the JN.1-adapted BNT162b2 COVID-19 vaccine in high-risk groups, real-world effectiveness of the Abrysvo vaccine against RSV-related lower respiratory tract disease, and analyses of COVID-19 vaccine uptake in children. The results from these studies will be presented during oral and poster sessions at the conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013078360) on October 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
